OpenEvidence, the artificial intelligence platform dubbed the ‘ChatGPT for doctors,’ has surged to a $12 billion valuation in its latest funding round, doubling its worth in mere months amid explosive growth in clinician adoption. The Massachusetts-based startup, which sifts through millions of medical journals to deliver precise answers to physicians, secured the valuation in a round led by Thrive Capital and DST Global, according to a CNBC report published Tuesday.
Trained on peer-reviewed sources like the Journal of the American Medical Association and the New England Journal of Medicine, OpenEvidence enables verified medical professionals to query vast medical knowledge bases for free, supported by advertising revenue. The platform’s rapid ascent reflects investor confidence in AI’s ability to streamline clinical decision-making, with usage now spanning a significant portion of U.S. doctors.
Growth Trajectory Accelerates
Prior to this milestone, OpenEvidence raised $200 million at a $6 billion valuation in October 2025, as detailed in a TechCrunch article. That round followed a $210 million Series B at $3.5 billion in July 2025, highlighting a pattern of valuation doublings every few months. Posts on X from industry observers like Healthcare AI Guy noted the firm’s handling of 15 million clinical consultations monthly by late 2025, up from 8.5 million earlier that year.
Revenue has kept pace, with reports from The Information in December 2025 indicating $150 million in recurring revenue from ads alone, achieving 90% gross margins even after compute costs, on fewer than one million users. This efficiency stems from the platform’s focus on retrieval-augmented generation, minimizing hallucinations by grounding responses in 35 million vetted documents.
Investor Backing Deepens
Thrive Capital and DST Global’s leadership in the current round builds on prior investments from GV and Kleiner Perkins. A Tech Funding News piece on the $6 billion raise emphasized plans for global expansion and new diagnostic tools. OpenEvidence’s free access model for professionals has driven viral adoption, with 40% of U.S. doctors reportedly using it by mid-2025, per X discussions citing company metrics.
The startup’s three-year track record includes partnerships with 11 top medical journals, feeding its AI with authoritative content. A New York Times report on the October funding highlighted skyrocketing usage among doctors, nurses, and others, drawing parallels to general-purpose AI tools but tailored for high-stakes medical queries.
Competitive Pressures Mount
As OpenEvidence scales, rivals like OpenAI’s ChatGPT Health, launched in January 2026, enter the fray. That product connects user medical records and wellness apps but disclaims diagnostic use, per a CNBC article. X posts from analysts contrast OpenEvidence’s clinician focus with consumer-facing tools, noting its edge in evidence-based responses.
Becker’s Hospital Review covered December 2025 reports of a $250 million equity raise at $12 billion, underscoring the firm’s momentum since its October valuation. OpenEvidence’s ad-supported model avoids subscription friction, fueling organic growth among time-strapped physicians who conduct millions of queries monthly.
Technical Edge in Evidence Synthesis
DeepConsult, a recent feature, provides PhD-level evidence syntheses, as mentioned in X updates from July 2025. The platform’s low hallucination rate, achieved through rigorous sourcing, sets it apart in a field plagued by AI inaccuracies. The Information reported the $12 billion target in a $250 million raise, signaling sustained investor appetite despite broader AI market volatility.
Founded just three years ago, OpenEvidence now powers consultations for a quarter-million U.S. doctors, per X posts from Vercel CEO Guillermo Rauch in January 2025. Its Next.js and Vercel infrastructure supports seamless scaling, as noted in those discussions.
Path to Monetization Maturity
With revenue tripling from August 2025 levels, OpenEvidence eyes further ad optimization and potential enterprise features. CNBC’s latest coverage confirms the $12 billion post-money valuation, positioning it among elite AI unicorns. Industry insiders on X hail its $100 million-plus annual run rate as a benchmark for applied AI profitability.
Global ambitions include non-English language support and deeper integrations with electronic health records. As competitors proliferate, OpenEvidence’s moat lies in its clinician-first design and trusted data partnerships, ensuring it remains a staple in daily medical practice.
WebProNews is an iEntry Publication